William Blair analyst Tim Lugo noted that Sarepta Therapeutics released the first functional data from its limb girdle muscular dystrophy-2E gene therapy trial, pointing out that SRP-9003 produced a significant improvement across all functional measures at nine months post-treatment. He views the new data as demonstrating the depth of the company's gene therapy pipeline and thinks safety results from these patients will "be of high interest for investors over the next six months," since clean safety could have a positive read-through to the four gene therapy assets to target the additional LGMD subtypes. Lugo has an Outperform rating on Sarepta shares.